Genmab A/S (CPH:GMAB)
1,352.50
-29.50 (-2.13%)
Aug 11, 2025, 11:00 AM CET
Genmab Revenue
Genmab had revenue of $925.00M USD in the quarter ending June 30, 2025, with 18.74% growth. This brings the company's revenue in the last twelve months to $3.65B, up 32.97% year-over-year. In the year 2024, Genmab had annual revenue of $2.99B with 22.32% growth.
Revenue (ttm)
$3.65B
Revenue Growth
+32.97%
P/S Ratio
3.67
Revenue / Employee
$1.36M
Employees
2,682
Market Cap
85.00B DKK
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.99B | 545.24M | 22.32% |
Dec 31, 2023 | 2.44B | 358.99M | 17.23% |
Dec 31, 2022 | 2.08B | 796.62M | 61.88% |
Dec 31, 2021 | 1.29B | -374.23M | -22.52% |
Dec 31, 2020 | 1.66B | 855.79M | 106.20% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Novo Nordisk | 311.94B |
Coloplast | 27.79B |
Demant | 22.42B |
ALK-Abelló | 5.71B |
H. Lundbeck | 22.95B |
Ambu A/S | 5.83B |
Zealand Pharma | 55.69M |
Bavarian Nordic | 6.23B |
Genmab News
- 2 days ago - Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Benzinga
- 2 days ago - Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Benzinga
- 3 days ago - Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Genmab A/S 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 3 days ago - Genmab rises on late-stage trial win for AbbVie-partnered lymphoma therapy - Seeking Alpha
- 3 days ago - Genmab reports 1H results - Seeking Alpha
- 3 days ago - Genmab Announces Financial Results for the First Half of 2025 - GlobeNewsWire
- 3 days ago - Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) - Business Wire